Breaking News

Countrywide's Mozilo Said to Face U.S. Suit Over Subprime Loans
Tweet TWEET

Actinium to Present at the 16th Annual BIO CEO & Investor Conference

  Actinium to Present at the 16th Annual BIO CEO & Investor Conference

Company Looks Forward to Communicating its Exciting Prospects and Meeting with
                             Conference Attendees

BIO CEO & Investor Conference 2014

Business Wire

NEW YORK -- February 5, 2014

Actinium Pharmaceuticals, Inc. (OTCQB:ATNM.OB) ("Actinium" or "the Company"),
a biopharmaceutical Company developing innovative targeted payload
immunotherapeutics for the treatment of advanced cancers, announced today that
Dr. Kaushik J. Dave, President and CEO, will present at the 16th Annual BIO
CEO & Investor Conference from February 10^th to 11^th, 2014. Dr. Dave will
present an overview of the company on Tuesday, February 11, 2014 at 1:30 pm
ET.


Presentation Information:

Date:        Tuesday, February 11, 2014
Time:           1:30 pm ET
Location:       The Waldorf-Astoria Hotel: Conrad Room, New York, NY
Webcast:        http://www.veracast.com/webcasts/bio/ceoinvestor2014/68234189.cfm
                

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (ATNM.OB) is a New York-based biopharmaceutical
company developing innovative targeted payload immunotherapeutics for the
treatment of advanced cancers. Actinium's targeted radiotherapy is based on
its proprietary delivery platform for the therapeutic utilization of
alpha-emitting actinium-225 and bismuth-213 and certain beta emitting
radiopharmaceuticals in conjunction with monoclonal antibodies. The Company’s
lead radiopharmaceutical Iomab™-B will be used in preparing patients for
hematopoietic stem cell transplant, commonly referred to as bone marrow
transplant. The Company is conducting a single, pivotal, multicenter Phase 3
clinical study of Iomab™-B in refractory and relapsed Acute Myeloid Leukemia
(AML) patients over the age of 55 with a primary endpoint of durable complete
remission. The company’s second program, Actimab-A, is continuing its clinical
development in a Phase 1/2 trial for newly diagnosed AML patients over the age
of 60 in a single-arm multicenter trial. For more information, please visit
www.actiniumpharmaceuticals.com.

For more information:

Visit our web site www.actiniumpharmaceuticals.com

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains “forward-looking statements” as defined in the
Private Securities Litigation Reform Act of 1995. These statements are based
on management's current expectations and involve risks and uncertainties,
which may cause actual results to differ materially from those set forth in
the statements. The forward-looking statements may include statements
regarding product development, product potential, or financial performance. No
forward-looking statement can be guaranteed and actual results may differ
materially from those projected. Actinium Pharmaceuticals undertakes no
obligation to publicly update any forward-looking statement, whether as a
result of new information, future events, or otherwise.

Contact:

Actinium Pharmaceuticals, Inc.
Investor/Media Relations:
Corey Sohmer, 646-459-4201
csohmer@actiniumpharmaceuticals.com
 
Press spacebar to pause and continue. Press esc to stop.